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Introduction
Glycogen storage disease type I (GSD1) is a metabolic disorder characterized by severe hypoglycaemia associated with hepatic, renal and intestinal disorders [1] . This inborn disease is due to a deficiency in glucose-6 phosphatase (G6Pase) activity. G6Pase is an essential enzyme of endogenous glucose production. Patients affected with GSD1 are therefore unable to maintain blood glucose concentration outside the time of meals and suffer from severe hypoglycaemic episodes if they are not managed by continuous feeding [2] [3] [4] . GSD type 1a and type 1b respectively correspond to inherited mutations in the genes that encode the catalytic subunit (G6PC) and the transporter unit (G6PT) of the G6Pase system [1, 2, 5, 6] . The G6pc gene is expressed in the liver, kidney, and intestine, and these are the only organs that release glucose into the blood circulation [7] [8] [9] [10] .
G6Pase deficiency leads to accumulation of glucose-6 phosphate (G6P), glycogen, and triglycerides in the liver and kidneys of patients. This results in marked hepatomegaly and nephromegaly. In the liver, the long term complications of G6Pase deficiency include focal nodular hyperplasia and more often hepatocellular adenomas (HCA) with risk of malignant transformation [11, 12] . These tumours are often bleeding, multiple and non-encapsulated.
The current treatments to prevent hypoglycaemia are based on nocturnal nutrition [13] .
When HCA or liver failure occur, the management strategies are resection of the tumour and/or liver transplantation [14, 15] .
To gain further insights into the long-term mechanisms of the disease and to evaluate potential treatment strategies, an animal model with sufficient life expectancy is required.
Identification of the G6pc gene in 1993 has enabled a G6pc-knockout mouse model to be developed [16, 17] , as well as the evaluation of gene therapy approaches to correct G6pc deficiency ( [18, 19] , see [20] for review). However, long-term complications cannot be evaluated because even with continuous glucose therapy, the total G6pc knock-out mice rarely live to be over 3 months of age [16] . To investigate the long-term biology and 4 pathogenesis of GSD-1a, we generated liver-specific G6pc -/-mice by an inducible CRE (CRE ERT2 ) strategy. We give a detailed characterization of this novel GSD1a mouse model over 18 months following inactivation of the G6pc gene in the liver.
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MATERIALS AND METHODS
Generation of B6.g6pc lox mice
The targeting vector used for the homologous recombination strategy is shown in Figure   1A and contained a 4. Mouse genotypes were determined from genomic DNA by PCR, with specific primers (Table 1 , see Figure 1 ). Genomic DNA was extracted from tissues in PCR Direct Lysis buffer (Euromedex).
Magnetic resonance imaging
As previously described [24, 25] , we performed MRI scans on mice anesthetized by isoflurane inhalation. This was done using a horizontal Biospec-7T Bruker system (Bruker, , matrix 256 x 192, 36 or 48 slices, slice thickness 0.5 mm, RARE factor =8.
As previously described [24] , the sequence was synchronized with respiration using balanced acquisitions over several respiratory periods with an effective repetition time (TR) of about 6 sec. Reading of MR images to detect adenomas was performed by a trained radiologist who had over fifteen years of experience.
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Metabolic studies
Blood was withdrawn from the tail vein and collected into EDTA or sodium fluorure/oxalate (anticoagulant). Plasma glucose, triglycerides, total cholesterol, uric acid and lactate concentrations were determined with Biomérieux colorimetric kits. Glucose-6 phosphate and glycogen determinations were carried out on frozen tissue homogenates as previously described [26, 27] .
Gene expression analysis
Mice were killed by cervical dislocation 6 h after food removal. The frozen tissues were sampled, and G6Pase and PEPCK activities determined as previously described [10, [28] [29] [30] . Immunoblotting was carried out using purified anti-rat G6PC (use at 1:1,500) or anti-PEPCK (use at 1:5,000; Santa Cruz Biotechnology) antibodies [31] . Total RNAs were isolated from tissues with TRIzol reagent (Invitrogen). Reverse transcription and real-time PCR were performed as previously described [32] , using sequence-specific primers ( Table   1 ). The mouse ribosomal protein mL19 transcript (Rpl19) was used as a reference.
Histological analysis
Tissues were fixed with 10% formalin and embedded in paraffin. Cross-sections (5 µm thick) were cut and stained with hematoxylin and eosin (H&E), periodic Acid Schiff (PAS) and picrosirius red staining. The slides were examined on a Coolscope microscope (Nikon, Tokyo, Japan).
Statistical analyses
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RESULTS
Generation of a time-dependent and liver-specific deficiency of G6Pase in mice
We disrupted G6Pase activity in the liver, by time dependent (conditional) and tissuespecific invalidation of the G6pc gene, based on a CRE-lox strategy. As endogenous glucose production, especially from the liver, is critical during the neonatal period (because of the low content of glucose in milk) [33, 34] , we have induced gene deletion in adult mice. 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 Expression of the genes encoding glucose-6-phosphate translocase (G6PT, Slc37a4) and the transporter subunit of G6Pase remained unchanged ( Figure 2E ). Expression of the ubiquitous (non gluconeogenic) glucose-6-phosphatase-related protein (G6PC3 or UGRP) was also unaffected ( Figure 2F ).
Metabolic effects of hepatic G6pc deficiency in mice
The male and female L-G6pc -/-mice showed similar survival rates to C57Bl/6J control (wt) and L-G6pc +/-heterozygous mice (data not shown). However, in contrast to total G6pc -/-mice, which are reported to have growth retardation [16] , the loss of G6Pase specifically in the liver during adulthood had only marginal effect, if any, on weight gain ( Figure 3A ).
Therefore, L-G6pc -/-mice are fully viable and do not require glucose therapy to survive [16] . After some hours of fasting, the blood glucose concentration in L-G6pc -/-mice could be lowered to about 3 mM (data not shown). This is consistent with the crucial role of hepatic glycogenolysis in endogenous glucose production during the early post-absorptive state. However, in the fed state, mean blood glucose concentration in L-G6pc -/-mice was similar to L-G6pc -/+ and control mice ( Figure 3B ). The blood glucose concentrations of L-
G6pc
-/+ mice were similar to those of control mice (around 150 mg/dL), even after 6h of fasting (data not shown). This is consistent with the absence of blood glucose problems and any pathological phenotype in heterozygous human patients [3] .
Biochemical analyses revealed highly disturbed plasma parameters just after deletion of G6pc in the liver. After ten days, L-G6pc -/-mice had plasma triglyceride and uric acid concentrations that were three times as high as those in control mice as well as plasma cholesterol concentrations that were twice as high ( Figures 3C-E) . L-G6pc -/-mice also had a plasma lactic acid concentration that had increased by 50% compared with control mice ( Figure 3F ). These concentrations remained high one month after gene deletion, but they 11 then normalized with time; all metabolic plasma parameters except for cholesterol were normalized after 18 months ( Figures 3C-F) .
LG6pc-/-mice develop hepatomegaly and steatosis
As in GSD-1a patients and total G6pc knock-out mice, loss of hepatic G6PC led to accumulation of hepatic glucose-6 phosphate (G6P), glycogen, and triglycerides, which resulted in hepatomegaly and steatosis ( Figure 4 ). The livers of L-G6pc -/-mice were enlarged and pale ( Figure 4A ) and accounted for about 8% of total body mass, versus only 4% in control mice ( Figure 4C ). The deposition of glycogen increased between 10 days and one month after deletion, to reach about 50 mg of glycogen/g in L-G6pc -/-liver at 18 months Figure 5I ). In contrast with total G6pc knock-out [16] , the kidneys and intestine in L-G6pc -/-mice did not accumulate any glycogen. After 18 months, the weight (0.16±0.01g for L-G6pc -/-versus 0.15±0.1g for controls) and histological features of L-G6pc -/-kidneys were also completely normal ( Figure 5J ).
Late appearance of hepatocellular adenomas in L-G6pc -/-mice
Because of the short lifespan of total G6pc -/-mice in the absence of glucose or gene therapy treatment, there was no possibility of detecting HCA. However, in the present study, using MRI, we were able to evaluate the development of nodules in the liver of L-
G6pc
-/-mice. MRI was performed every three months, from 3 to 18 months after gene deletion. In less than 15% (3 out of 26) of L-G6PC -/-livers, small lesions could be detected 12 as early as 9 months (data not shown). In about 30% (8 out of 26) of L-G6PC -/-mice, small nodules in the liver of about 1 mm diameter were first detected after one year ( Figure 6A ). In most cases (80%), the hepatocytes within the nodule were large and swollen, with pale cytoplasms ( Figures 6 G and 6I) . Areas of necrosis and inflammation were seen within the nodules ( Figure 6I ). The tumour shown in Figure 6G proved to be an adenoma. In a few cases (about 20%), the hepatocytes within the nodules were small, suggesting the development of a "precarcinoma" lesion ( Figures 6H and 6J ). Areas of necrosis and numerous foci of inflammation were also present within these nodules (data not shown). In no case, pericellular fibrosis was observed around hepatic nodules. Moreover, no atypia was noted in any of the nodules. No mice developed hepatocellular carcinoma in the course of this study. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 13
DISCUSSION
The maintenance of blood glucose levels within a narrow range (about 1g/L) is a critical physiological function. Outside of the time of meals and during fasting, endogenous glucose production is wholly responsible for maintaining plasma glucose levels. Glucose can be produced only in the liver, kidney, and intestine, because these are the only organs known to express G6Pase, the key enzyme for endogenous glucose production (for review see [9] ). Among these organs, the liver has a special role because it is able to rapidly mobilize glucose stored under the form of glycogen. Although the liver is the main glucoseproducing organ under post-absorptive conditions, we hypothesized that the inactivation of G6pc in the liver only would not be lethal, because of compensatory glucose production by the kidneys and intestine. This type of compensation has already been reported during the anhepatic phase of liver transplantation in humans [35] , and has been suggested in mice with inactivation of Pck1 in the liver [36] . In line with our hypothesis, L-G6pc -/-mice are normoglycemic in the fed state. This strongly suggests that glucose release by the kidney and intestine is sufficient to exquisitely regulate blood glucose concentration in L-G6pc -/-mice when unrestrained food is available. Furthermore, L-G6pc -/-mice had a normal survival rate, which allowed us, for the first time, to evaluate the development of GSD1a pathology in the livers of the mice, up to 18 months of age.
As expected, the liver of L-G6pc -/-mice is rapidly enlarged, due to the accumulation of glucose-6 phosphate, glycogen, and triglycerides. In parallel, there is a rapid increase in plasma triglycerides, cholesterol, lactic, and uric acids, as also observed in human GSD1a patients and in total G6pc knock-out mice [3, 4] . Together with the absence of kidney and gut deficiency and phenotype in L-G6pc -/-mice, this strongly suggests that the liver deficiency may be fully responsible for the deregulation of plasma parameters in GSD1a.
Whereas some liver parameters tended to worsen with time (e.g. liver TG content), others
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(blood parameters) progressively decreased towards control values (e.g. uricemia and lactatemia). This suggests that there are some compensatory mechanisms taking place over time to correct the primary defaults initiated by the liver deficiency. Interestingly, a comparable improvement of blood biochemical profile was also observed after some months in the total G6pc knock-out mice surviving thanks to pre-weaning management with glucose injection and post-weaning management with Nutragel and glucose added to the drinking water [37] . However, as in LG6pc -/-mice, liver histology and glycogen accumulation did not improve with aging [37] . Therefore, it is probable that a satisfying control of blood glucose could explain this amelioration (dependent either on exogenous supply or on compensation by extrahepatic endogenous sources).This is also in line with the observation that GSD1a pathology is better tolerated with patient aging, and that some of the metabolic plasma parameters have been reported to be at least partially corrected with time [3] .
To detect the putative appearance of hepatic adenomas as soon as possible while preserving the living animal, we used MRI, a powerful imaging technique, which allowed us to identify hepatic nodules about 1 mm in diameter. The first nodules were detected at 9 months of age, and after 18 months all livers in L-G6pc -/-mice showed at least one largesized lesion. As in human GSD1a, the adenomas were multiple, non-encapsulated, and in about 20% of cases, showed features of pre-carcinomas. It should be noted that adenomas were first detected at 9 months, a time when several plasma parameters had been normalized. However, this late detection cannot exclude that the development of adenomas may have started much earlier but they were not large enough to be detected by MRI. However, it is important to note that the development of adenoma appeared rather lately, whilst liver steatosis tended to worsen (see Figure 4 ). In the same time, several plasma parameters were markedly corrected, suggesting that the development of HCA was dependent on the alteration of liver metabolism and not on the deregulation of the 15 plasma parameters. Moreover, intrahepatic metabolic disturbances induced by G6Pase deficiency had the capacity to initiate adenoma formation in all of the livers studied.
Furthermore, even if hepatocellular carcinoma was not observed, a substantial proportion of the adenomas could be prone to develop into carcinomas.
In conclusion, we report the characterization of a novel animal model of GSD1a, which is exclusively targeted to the liver. We demonstrate that L-G6Ppc -/-mice have all the hepatic symptoms of the human pathology, including hepatomegaly, steatosis, glycogen overload.
L-G6pc -/-mice also have the expected dysregulations of plasma metabolites related to liver function such as triglycerides, cholesterol, lactic and uric acids. Our animal GSD1a model is perfectly viable without treatment and is normoglycaemic when food is available.
Because of this, for the first time we are able to report that the development of adenomas is bound to happen with time in GSD1a livers. In addition, a significant proportion of these adenomas exhibit the features of pre-carcinomas. Because of its viability, this new animal model will be extremely useful for a better understanding of the pathological mechanisms of GSD1a. It will also be of value in assessing the effects of food quality on delaying the deleterious consequences of the disease (e.g. adenomas). Our model should be able to help refine the different gene therapy approaches aimed at correcting G6Pase expression in the liver. Finally, in the near future, the CRE-lox approach that was used to generate the liver-deficient model, will allow us to assess the consequences of kidney or intestine pathology. This will be based on the use of a CRE recombinase expressed under the control of adapted gut or kidney gene promoters to specifically target the deficiency to either organ. 4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 25 Table 1 Oligodeoxyribonucleotide primer sequences for PCR (top) and qPCR (bottom) 
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